Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.

Journal of medicinal chemistry - 23 Jul 2020

Cheng Junfei, Li Yu, Wang Xu, Dong Guoqiang, Sheng Chunquan

Abstract excerpt

KRAS-PDEδ protein-protein interaction represents an appealing target for cancer therapy. However, fast release of high-affinity inhibitors from PDEδ hampered drug binding affinity and antiproliferative activity. To overcome the limitations, the first proteolysis-targeting chimeric (PROTAC) small molecules targeting PDEδ were designed. By employment of PDEδ inhibitor deltazinone (2) and cereblon ligand...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclic Nucleotide Phosphodiesterases, Type 6
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Structure

Share to Phosphodiesterase Inhibitors

Share to Proteolysis

Share to Pyrazoles

Share to Pyridazines

Share to Rats, Sprague-Dawley

Source

Identifiers

PMID: 32603594
DOI: 10.1021/acs.jmedchem.0c00929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.PMID 32603594Read ↗

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read ↗

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.Semantic proximity Read ↗

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACsSemantic proximity Read ↗

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera DegradersSemantic proximity Read ↗

Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer.Semantic proximity Read ↗

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein.Semantic proximity Read ↗

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.Semantic proximity Read ↗

PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRasSemantic proximity Read ↗

PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.Semantic proximity Read ↗

Rational design of DKK3 structure-based small peptides as antagonists of Wnt signaling pathway and in silico evaluation of their efficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.